Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS2149005 A
Publication typeGrant
Publication dateFeb 28, 1939
Filing dateNov 3, 1936
Priority dateNov 9, 1935
Publication numberUS 2149005 A, US 2149005A, US-A-2149005, US2149005 A, US2149005A
InventorsBockmuhl Max, Middendorf Leonhard, Starck Werner
Original AssigneeWinthrop Chem Co Inc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Shaped medicinal preparation
US 2149005 A
Images(2)
Previous page
Next page
Description  (OCR text may contain errors)

Patented Feb. 1939 NITED STATES SHAPED MEDICINAL PREPARATION Max Bockmiihl, Frankfort-on-the-Main-Hochst,

Leonhard Middendorf,Frankfort-on-the-Main- Sindlingen, and Werner Starck, Hofheim in Taunus. Germany,

assignors to Winthrop Chemical Company, Inc., New York, N. Y., a corporation of New York No Drawing. Application November 3, 1936, Serial No. 109,022. In Germany November 9, 1935 4 Claims.

The present invention relates to shaped methermore, the resorption of the vehicle occurs 1.5 very slowly there is the danger that part of the molten mass will flow from the cavities whereby an exact dosing ofthe medicine is made impossible. Finally most of the fats readily become rancid and havethen an irritating efiect 20 upon the mucous membranes. For a long time therefore, the function of basis material for shaped medicinal preparations has been shared by masses prepared from solutions of gelatin, agar-agar and the like in glycerine and water.

25 But also these vehicles show many defects. They dry readily when stored whereby their solubility in the cavities is diminished.

Furthermore, they constitute a nutrient medium for Hyphomycetes and bacteria. They are 30 liable to become mouldy and to form in the cavities an undesired and in certain cases even noxious nutrient medium for pathogenic bacteria.

Attempts which have been made to remove the drawbacks associated with these several vehicles 35 have not shownany practical results. Also swelling bodies which are often used for medicinal preparations to be introduced into the urethra or openings of wounds are not free from drawbacks. They also become hard when they are 40 stored up and then break down in the cavities only with difilculty.

Now we have found that polyalkylene oxides and the derivatives thereof are suitable vehicles for the manufacture of shaped medicinal preparations to be introduced into the cavities. In contradistinction to the fatty vehicles the melting point of the new vehicles is of no importance because their function does not depend on fusion but on dissolution in the secretion of the cavity.

The medicinal preparations which may be prepared according to our present invention have also the following favorable properties. When they are stored they are not decomposed and do not dry. They mix well and can 55 be shaped in a solid as well as in a molten state with most of the medicines. The preparations made with their aid have an unobjectionable solidity and persistence of form. As these new vehicles are soluble in water and in lipoids the medicinal preparation quickly dissolves in the-6 cavities so that the medicines contained in it can rapidly and completely be resorbed.

The new vehicles are physiologically indifferent, nonirritant and odorless and are resistant to the tropical climate. In consequence of the 10 surface activity of the new vehicles a very high degree of distribution of the incorporated medicines is obtained. J

Polyalkylene oxides and especially polyethylene oxide, which has been polymerized up to a waxlike consistency are, for instance, suitable; furthermore the derivatives of the polyalkylene oxides, especially the reaction products of ethylene oxide upon organic compounds which contain hydroxy-, carboxy-, aminoor amido-groups and among these especially those which have been obtained by the action of 10 to 20 molecular proportions of ethylene oxide upon 1 molecular proportion of the organic compound in question especially of a compound containing at least 10 5 carbon atoms. The compounds, for instance, which are obtained by the action of ethylene oxide upon castor oil, ricinole'ic acid or oleyl alcohol are especially suitable.-

For the preparation of the solid medicinal preparations there may, of course, also be used mixtures of the new vehicles. According to the desired purpose there may also be used suitable adjuvants and corrigents, such as glycerine, water, small proportions of fat, hydrocarbons having a high molecular weight and the like.

We have furthermore found that polyalkylene oxides and their derivatives may be used with the same result for the preparation of pills, tablets and the like. It is know that those medicinal preparations, made in known manner, often become hard when they are stored and then break down only very slowly or insufiiciently in the stomach or intestine. The same is true of tablets and dragees. Medicinal preparations to be administered per 0s and free from the disadvantages mentioned may be made by the invention. Also in this case widely differing derivatives of the polyalkyiene oxides may be used. Adjuvants of quite difierent kinds may also be used therewith.

The following examples illustrate the invention but they are not intended to limit it thereto; the

parts are by weight:

(1) Morphine suppositories (4) Papaverine tablets Parts Parts Morphine hydrochloride 0.5 Papaverine hydrochloride 4 Very pure, bleached polyethylene oxide 227 Very pure, bleached polyethylene oxide 33 Condensation product from ethylene oxide Glycerine 3 and ricinoleic acid 22. 3 Water 22. 2

(2) Suppositories prepared from dimethylaminophenyldimethylpyrazolone, sodium phenyldimethvlpurazolonemethylammomethane sulfanate and urethane Parts Dimethylaminophenyldimethylpyrazolone 40 Sodium phenyldimethylpyrazolonemethylaminomethane sulfonate 60 Urethane 45 Very pure, bleached polyethylene oxide 250 (3),Small rods containing the compound prepared from gelatose with silver nitrate Parts The compound prepared from gelatose with silver nitra 0. 25 Very pure, bleached polyethylene oxide-" 42 The condensation product from ethylene oxide and ricinoleic acid 4 45 Water 4 The mass which is prepared as described in Example l is poured into hollow moulds for rods.

The papaverine is made into a paste with the glycerine and the polyethylene oxide which has been liquefied by heating it on a steam bath is then stirred in. The mass is either poured into hollow moulds and allowed to cool or it is poured onto a glass plate or the like where it is allowed to harden and is then cut to form tablets.

(5) Pills prepared from cafl'eine-phenylethylmalonyl-urea Parts Cafl ln 2.5 Phenylethylmalonyl-urea 5 Very pure, bleached polyethylene oxide 15 Sugar syrup 5 The phenylethylmalonyl-urea and the cafieine are mixed with the polyethylene oxide which previously has been pulverized and the mixture is kneaded with the sugar syrup to a plastic mass. Pills are formed from this mass in the usual manner.

We claim: I

1. Shaped medicinal preparations comprising a pharmacologically active substance and a vehicle consisting of polyethylene oxide.

2. Shaped medicinal preparations comprising a pharmacologically active substance, a compound obtained by the interaction of ethylene oxide and ricinoleic acid and a vehicle consisting of polyethylene oxide.

3. Shaped medicinal preparations comprising a pharmacologically active substance, a compound obtained by the interaction of ethylene oxide and castor oil and a vehicle consisting of polyethylene oxide. a

4. Shaped medicinal preparations comprising a pharmacologically active substance, 8. compound obtained by the interaction of ethylene oxide and oleyl alcohol and a vehicle consisting of polyethylene oxide.

MAX BocKMiiHL. LEONHARD MIDDENDORF. WERNER STARCK.

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US2457188 *May 24, 1945Dec 28, 1948Americaine IncBenzocaine solution
US2469618 *Sep 21, 1945May 10, 1949Eaton Lab IncVaginal suppository
US2498374 *Oct 5, 1945Feb 21, 1950Martin Francis EMethod and article for treatment of mammary glands
US2538127 *Feb 26, 1948Jan 16, 1951Searle & CoMedicated suppositories and bases therefor
US2540253 *Feb 8, 1949Feb 6, 1951Merck & Co IncGranulation process
US2584166 *May 25, 1948Feb 5, 1952Ayerst Mckenna & HarrisonSuppository
US2605209 *Nov 3, 1950Jul 29, 1952Lilly Co EliSolutions of barbituric compounds
US2681297 *Oct 31, 1950Jun 15, 1954Mattox And Moore IncVeterinary estrogen composition and administration method
US2698822 *Apr 28, 1951Jan 4, 1955Fougera & Co Inc ECardiac glycoside buccal composition
US2762746 *Nov 14, 1952Sep 11, 1956American Home ProdComposition for combating malaria and process of making same
US2791530 *Aug 31, 1953May 7, 1957Abbott LabStabilized fumagillin compositions
US2890983 *Jul 30, 1957Jun 16, 1959Monot Pierre Louis VictorExcipient
US2899361 *Jun 23, 1952Aug 11, 1959 Certificate of correction
US3087860 *Dec 19, 1958Apr 30, 1963Abbott LabMethod of prolonging release of drug from a precompressed solid carrier
US3149038 *Sep 5, 1961Sep 15, 1964Dow Chemical CoThin film coating for tablets and the like and method of coating
US3163576 *Jun 12, 1961Dec 29, 1964Olin MathiesonSuppository base comprising glycerin and a diester of polyethylene glycol
US3432592 *Aug 28, 1963Mar 11, 1969Ciba Geigy CorpInjection-moulded oral medicament in solid form
US3511914 *Jan 31, 1967May 12, 1970Schering CorpThroat lozenge vehicle
US3826232 *May 21, 1971Jul 30, 1974Pet Chem IncComposition and method for the control of fleas on domesticated animals
US3862311 *Jan 5, 1973Jan 21, 1975Ciba Geigy CorpNovel method of enhancing progestational endometrial proliferation with progesterone
US3876757 *Mar 16, 1973Apr 8, 1975Merz & CoContraception agent
US4151273 *Jun 13, 1978Apr 24, 1979The Regents Of The University Of CaliforniaSolid solution of griseofulvin in polyethylene glycol
US4265875 *Oct 19, 1979May 5, 1981Inveresk Research InternationalHydroxypropyl methyl cellulose
US4292300 *Jul 20, 1977Sep 29, 1981Inveresk Research InternationalControlled release suppositories
US4343789 *Jul 2, 1980Aug 10, 1982Yamanouchi Pharmaceutical Co., Ltd.Nicardipine and polyoxyethylene glycol
US4404183 *Jul 29, 1982Sep 13, 1983Yamanouchi Pharmaceutical Co., Ltd.Particle mixture of polyoxyethylene glycol and indomethacin or nicardipine
US4690822 *Mar 12, 1986Sep 1, 1987Fujisawa Pharmaceutical Co., Ltd.Carrier mixture of aqueous polymer and liquid oil
USRE29102 *Apr 2, 1976Jan 4, 1977Merz & Co.Polyethylene glycol suppository base, tartaric acid and sodium bicarbonate foaming agents
WO1982003747A1 *Apr 28, 1982Nov 11, 1982Int SpikeSystemic pesticide product and processes for making and using it
Classifications
U.S. Classification424/619, 424/DIG.150, 424/436, 514/772
International ClassificationA61K9/02, A61K9/20
Cooperative ClassificationA61K9/02, Y10S424/15, A61K9/2031, A61K9/2013
European ClassificationA61K9/20H6D, A61K9/02, A61K9/20H4